Matinas BioPharma Appoints New Directors, Updates Executive Contracts
Ticker: MTNB · Form: 8-K · Filed: Mar 14, 2025 · CIK: 1582554
| Field | Detail |
|---|---|
| Company | Matinas Biopharma Holdings, Inc. (MTNB) |
| Form Type | 8-K |
| Filed Date | Mar 14, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-changes, executive-compensation, employment-agreement
TL;DR
Matinas BioPharma adds two directors and revises CEO/CFO contracts. Board shakeup and executive pay changes.
AI Summary
Matinas BioPharma Holdings, Inc. announced on March 13, 2025, changes in its board of directors and executive compensation. Specifically, the company elected two new directors, Dr. Paul J. Hastings and Ms. Karen M. Smith, to its Board of Directors. Additionally, the company entered into new employment agreements with its Chief Executive Officer, Dr. Terry L. Horgan, and Chief Financial Officer, Ms. Suzanne H. McInnis, effective March 13, 2025, detailing their compensation and severance packages.
Why It Matters
The appointment of new directors and updated executive contracts can signal strategic shifts or confidence in leadership, potentially impacting the company's future direction and investor sentiment.
Risk Assessment
Risk Level: medium — Changes in board composition and executive compensation can indicate internal restructuring or strategic realignments that may carry inherent risks.
Key Players & Entities
- Matinas BioPharma Holdings, Inc. (company) — Registrant
- Dr. Paul J. Hastings (person) — Newly Elected Director
- Ms. Karen M. Smith (person) — Newly Elected Director
- Dr. Terry L. Horgan (person) — Chief Executive Officer
- Ms. Suzanne H. McInnis (person) — Chief Financial Officer
- March 13, 2025 (date) — Effective date of board changes and new employment agreements
FAQ
Who were the newly elected directors to Matinas BioPharma's Board?
Dr. Paul J. Hastings and Ms. Karen M. Smith were elected to the Board of Directors.
When were the new employment agreements for the CEO and CFO effective?
The new employment agreements for Dr. Terry L. Horgan (CEO) and Ms. Suzanne H. McInnis (CFO) were effective as of March 13, 2025.
What specific items are covered in the new employment agreements?
The new employment agreements detail compensation and severance packages for the Chief Executive Officer and Chief Financial Officer.
What is the principal executive office address for Matinas BioPharma?
The principal executive offices are located at 1545 Route 206 South, Suite 302, Bedminster, New Jersey 07921.
What is the IRS Employer ID Number for Matinas BioPharma?
The IRS Employer ID Number for Matinas BioPharma is 46-3011414.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 14, 2025 by Dr. Paul J. Hastings regarding Matinas BioPharma Holdings, Inc. (MTNB).